Drug intelligence / Profile preview

MINE

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

MINE is a chemotherapy regimen composed of Ifosfamide, Mitoxantrone, and Etoposide, with Mesna included as a uroprotectant. This combination is utilized in the treatment of certain lymphomas, such as intermediate-grade or immunoblastic non-Hodgkin's lymphoma. The regimen works by combining drugs that interfere with cancer cell division and growth through distinct mechanisms, aiming to maximize therapeutic effect while managing side effects.

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on MINE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MINE.

Explore the full profile